Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor The article by Prasad and colleagues1 reports that there has only been 1 randomized clinical trial (RCT) of the inferior vena cava (IVC) filter—the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) study.2 An additional RCT evaluating IVC filters in patients with cancer has been reported.3 Recognition of this RCT is of particular importance because it studied patients with cancer, who as a group are 6 times as likely to develop venous thromboses compared with the general population. Nearly 14 million Americans are living with cancer,4 and with the baby boom generation aging and an increasing life expectancy, the number of patients with cancer is expected to exceed 18 million by 2022.4
Barginear MF. The Inferior Vena Cava Filter. JAMA Intern Med. 2013;173(18):1754. doi:10.1001/jamainternmed.2013.8762